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Multiple-unit dosage forms are based on subunits such as granules, pellets, or mini-
tablets and they are usually delivered in hard gelatin capsules (1). The recent interest in
multiple-unit dosage forms is a result of the advantages they offer over the single-unit
systems (e.g., tablets). Multiple-unit forms offer more predictable gastric emptying, less
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Pellets containing theophylline as a model drug and mic-
rocrystalline cellulose, in a ratio of 6:4, were prepared by
the extrusion-spheronization method. The pellets were
coated with Eudragit® RS aqueous dispersions, containing
various amounts of pectin-chitosan complex and differ-
ent coating mass gains, using a fluidized-bed apparatus.
Twelve formulations were developed, which differed in
two factors: coating mass gain (10, 15 and 20%, m/m) and
the amount of pectin-chitosan complex (5, 10, 15 and 20%,
m/m). Drug release studies were conducted using the USP
apparatus I (basket) in dissolution media, mimicking the
conditions prevailing in the stomach, small intestine or
colon. Studies have shown that the drug release rate and
pattern were dependent on both of the two mentioned
factors. Some formulations showed bimodal and burst
drug release, being triggered in the colonic medium by
the action of pectinolytic enzymes. In formulations with
15 or 20% (m/m) of coating mass gain and 5 or 10% (m/m)
of pectin-chitosan, the burst drug release was eliminated
and replaced by the lag phase of drug release. In the case
of burst drug release in the colonic medium, formula-
tions with 20% (m/m) of coating mass gain and 15 or 20%
(m/m) of pectin-chitosan were found to be better than the
other formulations. Studies on the surface SEMs of un-
coated and coated pellets show that after coating, coated
pellets become smoother and exposure to pectinolytic en-
zymes in the colonic mediummay result in surface erosion.
Keywords: bimodal drug delivery, burst release, chitosan,
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dependent on the state of nutrition, less variance in transit time through the gastrointes-
tinal tract (GIT), a higher degree of dispersion in the digestive tract, less absorption vari-
ability, and a lesser risk of dose dumping than single-unit dosage forms (2).
Bimodal or sigmoidal drug release profiles, where release is slow in the initial stages
and increases to a faster release rate in some later stages, may be of significant therapeu-
tic benefit (3). In disease states such as nocturnal asthma, increased drug release rates
may help prevent the exacerbation of symptoms caused by circadian rhythms (4). Bi-
modal release profiles could be utilized so that drug release is slower in a region within
the GIT where absorption is good, i.e., small intestine and the lower GIT where drug ab-
sorption may be poor, i.e., the colon. The overall effect being to maintain therapeutic blo-
od drug levels throughout (5).
Natural or modified polysaccharides such as gelatin, dextran, chondroitin sulphate,
calcium pectinate, pectin and chitosan have been used as potential carriers for the oral de-
livery of drugs to the colon because they are safe, biodegradable and widely available (6).
Among these polymers, pectin and chitosan have shown particular promise, since
they are able to form a polyelectrolyte complex (PEC). Complexation of pectin with chi-
tosan allows control over drug release while maintaining the pectin ability to be degrad-
ed by colonic bacteria, thus potentially achieving bimodal delivery (5).
The major problems encountered with polysaccharides such as pectin and chitosan
are their high water-solubility and swelling properties in aqueous media. Films consist-
ing of pectin and chitosan are unable to prevent fast drug release during its transit through
the stomach and small intestine. However, incorporation of hydrophilic degradable po-
lysaccharides in water-insoluble film-forming polymers such as cellulosic or acrylic po-
lymers could provide a promising alternative. The integrity of such a mixed-film could
be better controlled by preventing fast swelling and solubilization of pectin and chitosan
during the transit from mouth to colon. On the other hand, the film degradability is
maintained by the pectinolytic enzymes of the colonic flora, which is expected to gener-
ate pores for drug release or coating disintegration during the colonic transit (7).
The objective of this paper was to develop and evaluate the potential of Eudragit®
RS, containing various amounts of pectin-chitosan complexes (as coating material) and
different coating mass gains, intended for bimodal or sigmoidal drug release from a
multiple-unit of theophylline pellets. In vitro dissolution studies have been carried out in
simulated GIT media on coated theophylline pellets. Influence of the pectin-chitosan
amount, coating mass gain, the presence of pectinolytic enzymes in the simulated co-
lonic medium and acidic dissolution environment on the drug release was also investi-
gated. Theophylline was used as a model drug, since it is known to be well absorbed
from the wide regions of the gastrointestinal tract (8).
EXPERIMENTAL
Materials
Theophylline anhydrous was supplied by BASF (Germany), Eudragit® RS and Eu-
dragit® L100-55 were kindly provided by Röhm Pharma GmbH (Germany). Microcrys-
300
A. Ghaffari et al.: Pectin/chitosan/Eudragit® RS mixed-film coating for bimodal drug delivery from theophylline pellets: Preparation
and evaluation, Acta Pharm. 56 (2006) 299–310.
talline cellulose (Avicel® PH 101) was supplied by FMC Corp. (USA). Pectin HM (High
Methoxylated) from citrus fruit and chitosan low molecular mass, 84.7% deacetylated,
viscosity 1% (m/V) solution in acetic acid 1% (V/V) is 34 mPas were purchased from
Sigma-Aldrich (UK). Pectinex® Ultra SP-L (pectinolytic enzymes extracted from Asper-
gillus niger) was kindly donated by Novo Nordisk Ferment (Switzerland). According to
the Pectinex® producer, it has a standard activity of 26000 pg mL–1 (pH 3.5). The Pec-
tinex® Ultra SP-L solution contains a mixture of pectinolytic enzymes, mainly polygalac-
turonases, pectin esterases and pectin lyases and was used to mimic the conditions in
the colon. The other materials were of pharmaceutical or analytical grade, and were used
as received.
Methods
Preparation of theophylline pellets. – Theophylline pellets were prepared by the extru-
sion-spheronisation method (laboratory unit, Gabler GmbH, Germany). A 100-g batch of
theophylline anhydrous and microcrystalline cellulose (Avicel® PH 101), in a mass ratio
of 6:4, was mixed in a plastic bag for 10 min, kneaded with 95 mL of deionized water
and loaded into the extruder (extruder type E-35, Gabler). Wet mass extrusion was car-
ried out shortly after moistening to avoid any water loss, using an axial type, single-
-screw extruder provided with a 1.0-mm screen (for both the orifice diameter and screen
thickness). The extruder rotation speed was kept constant at 90 rpm. The extrudates
were immediately transferred to a spheronizer (spheronizer type R-250, Gabler) equip-
ped with a crosshatch plate and processed at 1000 rpm rotating speed for 15 min. Pellets
were collected and dried in a hot air oven at 50 °C for 12 h.
Preparation of the polyelectrolyte complex (PEC) and coating dispersion. – In this study, due
to formulation of pectin and chitosan as biodegradable coating materials, first a complex
between two polymers was formed and then the complex was incorporated in Eudra-
git® RS films, since pectin-chitosan itself has no film-forming properties. Eudragit® RS is
a copolymer of acrylic acid and methacrylic esters with a low content of quaternary am-
monium groups. It was chosen as film-former because it gives water-insoluble, pH-inde-
pendent, low permeable films, which are inert to endogenous digestive secretions and
enzymes (9).
Chitosan was dissolved in 0.1 mol L–1 acetic acid and pectin was dispersed in dis-
tilled water. The chitosan solution was slowly added to the pectin aqueous dispersion.
Then, the pH of the mixture was adjusted to 5.4 with 0.1 mol L–1 HCl or 0.1 mol L–1
NaOH and allowed to react under mechanical stirring for 1 hour. After mixing, it was
filtered and the filter cake was washed with 0.1 mol L–1 acetic acid to remove free chi-
tosan and then washed with warm water until the filtrate became neutral. After being
dried at 50–60 °C, the PEC was dispersed in formic acid (10%, V/V). Then, appropriate
amounts of the pectin-chitosan complex suspension were added to the aqueous disper-
sion of Eudragit® RS30D. Eudragit® RS30D was previously mixed for 30 min with tri-
ethyl citrate (TEC) as a plasticizer (10%, m/m, related to the solid content of Eudragit®
RS30D).
Eudragit® RS requires addition of 10–20% of plasticizers in order to lower the mini-
mum film forming temperature (MFT) below 30 °C (9). The compositions of different
coating dispersions are presented in Table I.
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Coating processes. – Known masses of pellets (100 g) of 25-mesh were transferred into
a fluidized-bottom spray coating system assisted by a Wurster column (Uni-Glatt, Glatt
GmbH, Germany) and then coated with each dispersion medium (Table I). During the
coating operations, the aqueous dispersions were continuously stirred in order to pre-
vent sedimentation of the insoluble materials. The operating conditions during the coat-
ing process can be described as follows: inlet and outlet temperatures of drying air were
of 48–50 °C and 30–32 °C, respectively. Pneumatic spraying pressure and spraying rate
were set correspondingly at 1.5 bar and 10 mL min–1. After coating, the resulting coated
pellets were cured at 60 °C for 24 hours.
Drug content determination. – The drug contents of uncoated and coated pellets were
determined by HPLC analysis (10). The HPLC (LC1445 model, GBC Scientific Equip-
ment, Australia) consisted of a pump (LC1150 model) set at a constant flow rate of 2 mL
min–1, a variable UV detector (LC1205 model) set at 280 nm, and Eurospher®-100 C18
(4.6 × 250 mm) reversed-phase column, 5 m. The eluant solution consisted of a mixture
of acetonitrile and acetate buffer solution pH 4.5 (7:93). After determination of the drug
content, hard gelatine capsules No. 2 were filled manually with an appropriate amount
of coated pellets (equivalent to 200 mg of theophylline) for each formulation. Then, the
capsules were enteric-coated by alcoholic solution of Eudragit® L100-55 polymer in a
conventional coating pan (approximately 100 mg of polymer for each capsule).
Drug release study. – Drug release studies were conducted using the USP basket me-
thod (apparatus I) at 100 rpm and 900 mL of dissolution fluid at 37 ± 0.5 °C. Three en-
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a CMG: coating mass gain.
b Mean ± SD, n = 3.
teric-coated capsules of each formulation were tested individually in 0.1 mol L–1 HCl
(pH 1.5) for the first two hours, phosphate buffer pH 7.4 for the second three hours and
phosphate buffer pH 6.0 containing pectinolytic enzymes (4 mL L–1) for the third five
hours. These media were chosen to mimic the conditions in the stomach, small intestine
and colon, respectively. At predetermined time intervals, 5 mL of medium was sampled
and replaced by an equal volume of fresh medium. Samples were filtered, diluted and
analyzed. The amount of drug released was assayed spectrophotometrically at max =
270.5, 271.8 and 271.7 nm for the first to third medium, respectively.
Determination of size distribution of pellets. – Pellet size distribution was determined
using the sieve analysis method. Approximately 50 g of coated pellets were placed on
the top sieve in the sieve shaker (AS200 digit model, Retsch®, Germany) equipped with
10, 14, 18, 25, 35, 45 and 60-mesh US standard sieves and were shaken for 10 min. Orifice
sizes of the aforementioned sieves were 2000, 1410, 1000, 710, 500, 350 and 250 µm, re-
spectively. Finally, the mass of each fraction was measured.
Scanning electron microscopy (SEM). – Surface morphology views of both uncoated
and coated pellets, before and after the dissolution test, were photographed using a
scanning electron microscope (MV2300 model, Obducat CamScan Ltd, UK). Prior to ex-
amination, samples were gold sputter-coated to render them electrically conductive.
RESULTS AND DISCUSSION
Both uncoated and coated theophylline pellets were successfully produced using the
extrusion-spheronization and fluidized bed bottom spray coating systems, respectively.
In Table I, the actual coating mass gain (%, m/m) of each formulation of coated pellets
was calculated taking into account the relative decrease of drug content in coated pellets
companed to the initial drug content in uncoated pallets. The drug content in three
batches of coated pellets (F1) was found to be 98.4 ± 2.4%, indicating that the manufac-
turing process was quite reproducible.
Size distribution of the coated pellets (F1 formulation) was determined by the sieve
analysis method (Fig. 1). Approximately 60% (m/m) of the pellets were in size range of
710–1000 m, and 31% (m/m) were between 1000 to 1410 m. The mean size (dmean) of
880 m (880 ± 17) was obtained.
In the present investigation, pectin HM (as a polyanionic polymer) was complexed
with chitosan (as a polycationic polymer). The PEC formed between them reduced the
ionic charge, hydrophilicity and the swelling properties of both pectin and chitosan. It
was reported that the optimum pectin/chitosan ratio for PEC formation was somewhere
between 2:1 and 3:1 (11). Our findings from the viscosity studies suggest that 2:1 is closer
to the optimal ratio for PEC formation at pH 5.4 (data not shown). Thus, in the current
study, the pectin/chitosan ratio was kept constant at 2:1 for all formulations (F1–F12).
In our study, isolated films of the pectin-chitosan complex were prepared by the sol-
vent casting method in Teflon® Petri dishes and immersed in the following media: acidic
medium (0.1 mol L–1 HCl, pH 1.5), phosphate buffer pH 7.4 and phosphate buffer pH
6.0. These media simulate gastric, small intestine and colonic media, respectively. It was
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observed that the films dissolved easily after about 10 min in acidic medium, while they
swelled rapidly without any dissolution in the other two media. It was assumed that
pectin-chitosan complex in the mixed ternary blends (pectin/chitosan/Eudragit® RS)
could be dissolved and leached from the mixed-film; hence, an additional outer enteric-
-coating is necessary to prevent this undesired effect. After capsule filling with coated
pellets, capsules were enteric-coated by the alcoholic solution of Eudragit® L100-55 po-
lymer in a conventional coating pan. None of the enteric-coated formulations showed
any drug release in the first 2 hours in the simulated gastric environment.
Influence of the coating mass gain and pectin-chitosan content on the theophylline release
from coated pellets. – Effects of the mentioned factors on the drug release profiles were in-
vestigated in the F1–F12 formulations.
The theophylline release profiles obtained from enteric-coated F1–F4 formulations
(compositions shown in Table I) with 10% (m/m) of theoretical coating mass gain and dif-
ferent amounts of pectin-chitosan (5–20%, m/m, relative to the total amount of film) are
presented in Fig. 2a. It can be observed that, after an almost constant lag time of about
120–130 min, drug release happened due to the protective effect of the enteric coating.
The drug release rates were different, depending on the amount of pectin-chitosan incor-
porated in the film coatings. Drug release rates in phosphate buffer pH 7.4 (simulated
small intestine) were in the order F4 > F3 > F2 > F1. It was found that the higher were the
amounts of pectin-chitosan, the more drug was released. This effect was due to the swel-
ling-hydration ability of the pectin-chitosan complex. After 300 min, phosphate buffer
pH 7.4 was replaced by phosphate buffer pH 6.0 and 3.6 mL of pectinolytic enzymes in
900 mL of the medium was added. This commercially available mixture of specific en-
zymes with pectinolytic activity has shown to be closely correlated with that of the Bac-
teroides ovatus, the main colon producer of pectinolytic enzymes (12). After 10 min of
drug release in the colonic medium, the rate of drug release from formulations was
highly increased, which was probably caused by the degradation of pectin with pecti-
nolytic enzymes. It seems that a fast biodegradation and erosion process occurred with-
in the pectin-chitosan complex, which is in agreement with the results of release studies
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Fig. 1. Histogram plot of the size distribution of a coated theophylline pellet (F1).
causing a marked increase in the release rate. F1–F4 formulations deliver no drug under
in vitro conditions that simulate the stomach (pH 1.5), commence the release of drug at
moderate rates under conditions simulating the small intestine (pH 7.4) and accelerate
the release rate in the presence of pectinolytic enzymes (colonic medium, pH 6.0). Such a
system would be proper in the situation where a bimodal or sigmoidal drug release pro-
file is sought.
Fig. 2b shows the curves of theophylline release from enteric-coated F5–F8 formula-
tions (compositions in Table I). As can be seen, these release profiles are different from
those depicted for F1–F4 formulations in Fig. 2a. Contrary to F7 and F8, there is no dis-
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Fig. 2. Cumulative percent of drug release (mean
± SD, n = 3) vs. time profiles of: a) enteric coated
F1–F4 formulations, b) enteric coated F5–F8 formu-
lations, c) enteric coated F9–F12 formulations, d)
non-enteric coated F1 and F4 formulations and e)
enteric coated F12 formulation in the presence or
absence of pectinolytic enzymes in simulated co-
lonic medium. Vertical lines denote the time po-
ints for changes in dissolution media.
tinct increase in the drug release after 300 min in F5 and F6 formulations. The lower
amounts of pectin-chitosan in the F5 and F6 formulations compared to F7 and F8 formu-
lations may be responsible for this difference. Drug release from F5 and F6 formulations
is not bimodal and a little burst drug release can be observed for F7 and F8 formulations.
Fig. 2c illustrates the drug release profiles from enteric-coated F9–F12 formulations.
The dissolution profiles of F9 and F10 formulations are characterized by an initial latency
phase of almost no or very slow drug release in the period of 120–180 min and a second
lag phase from 300 to 360 min. These lag time periods depend on the pectin-chitosan
content and may be attributed to the time required for the dissolution media to diffuse
and stabilize the hydrodynamic exchanges across the mixed-films. After the lag phases,
the drug release from F9 and F10 formulations is linear as a function of time. Fig. 2c also
shows that F11 and F12 formulations have only one lag phase at 120–150 min and after
300 min; their drug release profiles follow a burst and bimodal release pattern. Owing to
the considerable burst drug release, the F11 and F12 formulations were found to be better
than the other formulations and they were selected as optimal formulations.
Chemical degradation is the most important mechanism for the biodegradation of
polymers. By introducing hydrolyzable functional groups into the polymer backbone,
polymer chains become labile to an aqueous environment and thus, chemical degrada-
tion initiates polymer erosion (13). Pectinex® Ultra SP-L used as a pectinolytic enzyme in
this research is capable of hydrolytic breakdown of pectin substrate (14). During poly-
mer degradation, the polymer breaks down into oligomers and monomers. Degradation
is the most important part of erosion (13, 15). The release of degradation products leads
to mass loss, which is a characteristic of erosion. The above-mentioned explanation may
help understand the possible reason for the burst drug release observed in this study.
Drug release mechanism for optimal formulations. – The release data for F11 and F12 were
fitted into various release equations and kinetic models first-order (16), zero-order, Hi-
guchi (17) and Korsmeyer and Peppas (18). As indicated by the value of R2, the zero-or-
der and Higuchi model were found to be efficient in describing the kinetics of drug re-
lease from F11 and F12 in the small intestine and colonic media, respectively. To explore
the release pattern, results of the release data of the aforementioned formulations were
also fitted to the Korsmeyer and Peppas equation Mt/M = k tn, where Mt/M is the
fraction of drug released after time t relative to amount of drug released at infinite time,
k is the rate constant and n is the diffusional exponent characterizing the transport me-
chanism (19). The n values for F11 and F12 in the simulated small intestine medium were
equal to 2.7328 and 2.5102, respectively, indicating that the drug release was governed
by super case-II transport. In colonic medium, n values were equal to 0.3854 and 0.402
for F11 and F12, respectively, pointing to Fickian diffusion.
Influence of acidic dissolution medium on the drug release from coated pellets. – In the pre-
vious section, it was mentioned that the isolated film of pectin-chitosan dissolved rap-
idly in acidic medium, while they swelled and showed no dissolution in the two phos-
phate buffer media. F1 and F4 (the former has 5%, m/m and the latter has 20%, m/m of
pectin-chitosan complex) as two example formulations were chosen for the dissolution
study under acidic conditions (Fig. 2d). Neither of the two formulations showed a bi-
modal release profile and a linear drug release pattern was observed for them. This ob-
servation may be explained by the pores (channels) formation mechanism whereby solu-
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tes are transported through the film. When the coated pellets were exposed to the acidic
medium, the pectin-chitosan moiety dissolved and was removed from the film, and con-
sequently the film became porous. After exposure to acidic medium, due to the higher
amount of pectin-chitosan incorporated in F4 vs. F1, the film porosity and drug release
rate from F4 will be higher than for F1.
Influence of pectinolytic enzymes on the theophylline release from coated pellets. – Studies
of Semdé et al. (20) on theophylline pellets coated with Eudragit® RS containing pectin
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Fig. 3. Scanning electron microscopy of the surface of: a) uncoated theophylline pellet, b) coated
theophylline pellet (F12 formulation, before dissolution), c) after 3 h dissolution in phosphate buffer
solution pH 7.4, d) after 3 h dissolution in phosphate buffer pH 7.4 and then 15 min in phosphate
buffer pH 6.0 with pectinolytic enzymes. Magnification: 400x for a and b, 130x for c and d.
b) d)
c)a)
HM or calcium pectinate gave unsatisfactory results. Their investigations showed that
the presence of pectinolytic enzymes in dissolution media resulted in decreased drug re-
lease rate. Nevertheless, our study showed that the presence of pectinolytic enzymes in
the colonic dissolution medium resulted in an increase of the drug release from most
formulations. Fig. 2e displays the drug release rate from the enteric-coated F12 formula-
tion. A significant difference (p < 0.001) was recorded for the drug release rate in the
presence vs. absence of pectinolytic enzymes.
Scanning electron microscopy. – Figs. 3a and 3b show the SEMs of the surface of un-
coated and coated pellets (F12 formulation), respectively. As can be seen, the uncoated
pellet surface became smoother after coating. Fig. 3c depicts the surface SEM of F12 coat-
ed pellets after 3 h dissolution in phosphate buffer pH 7.4 (simulated small intestine).
Fig. 3d exhibits the surface SEM of that formulation after 3 h in phosphate buffer pH 7.4
and then 15 min dissolution in the colonic medium. Bimodal drug release obtained in
the dissolution study agrees with the microscopic changes of coated pellets in the two
mentioned media. As can be seen in Fig. 3c, the surfaces of coated pellets at pH 7.4 are
very rough, probably due to film swelling. In the simulated colonic environment, the
pellets surfaces erode, which may be caused by the action of pectinolytic enzymes.
CONCLUSIONS
The optimal formulations for bimodal drug delivery were made up of theophylline
pellets having approximately 20% (m/m) of coating mass gain and 15 or 20% (m/m) of
pectin-chitosan. Zero-order was found to be a better fitting model for optimal formula-
tions in the simulated small intestine medium. In the simulated colonic medium, drug
release followed the Fickian diffusion transport or the Higuchi model.
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S A @ E TA K
Film-ovojnica smjese pektina, kitozana i Eudragita® RS za bimodalno
osloba|anje lijeka iz peleta s teofilinom: Priprava i evaluacija
ALIREZA GHAFFARI, MAHVASH OSKOUI, KAMRAN HELALI, KHOSROW BAYATI i MORTEZA RAFIEE-TEHRANI
Pelete s teofilinom kao modelnim lijekom i mikrokristalini~nom celulozom u om-
jeru 6:4 pripravljeni su metodom ekstruzije i sferonizacije. Pelete su presvu~ene vodenom
disperzijom Eudragita® RS koja sadr`i razli~ite koli~ine kompleksa pektina i kitozana i
razli~ite mase ovojnice, koriste}i ure|aj za fluidizaciju. Pripravljeno je 12 peleta koje se
razlikuju po masi ovojnice (10, 15 i 20%, m/m) i udjelu kompleksa pektina i kitozana (5,
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10, 15 i 20%, m/m). Osloba|anje ljekovite tvari prou~avano je u USP aparaturi I (s ko{a-
ricama) u medijima koji odgovaraju pH probavnog sustava. Dobiveni rezultati ukazuju
da brzina i na~in osloba|anja lijeka ovisi o oba spomenuta parametra. Iz nekih priprava-
ka osloba|anje je bimodalno, a posljedica je djelovanja pektinoliti~kih enzima iz kolona.
U pripravcima u kojima je udio ovojnice 15 ili 20% (m/m), a udio pektin-kitozana 5 ili
10% (m/m) osloba|anje je bilo polagano. Najbolji pripravci za naglo osloba|anje u pH
mediju podru~ja kolona sadr`avali su 20% (m/m) ovojnice i 15 ili 20% (m/m) pektin-kito-
zana. Prou~avanje oblo`enih i neoblo`enih peleta SEM metodom pokazuje da oblo`ene
pelete imaju glatkiju povr{inu, koja erodira uslijed djelovanja pektinoliti~kih enzima.
Klju~ne rije~i: bimodalna isporuka lijekova, naglo osloba|anje, kitozan, Eudragit® RS, film-ovojnica,
pektin, peleta
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